Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Our study highlights Acla as a promising anthracycline derivative for pediatric cancers, with potent anti-tumor efficacy and a superior safety profile, even following prior anthracycline exposure. These results support continued investigation of chromatin-damaging anthracyclines that can kill pediatric cancer cells without inducing genotoxic stress. In addition, our studies underscore the need to refine preclinical models to better understand both acute and chronic anthracycline toxicities in pediatric and adolescent populations.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2025-11-26
DOI
https://doi.org/10.1002/pbc.32169
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Shireen Ganapathi, Radhika A. Patel, Erolcan Sayar, Elizabeth R. Lawlor et al.
Pediatric Blood & Cancer
Chemotherapy-induced cardiotoxicity and mitigation
article

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Shireen Ganapathi, Radhika A. Patel, Erolcan Sayar, Elizabeth R. Lawlor, Lisa Maves, Jenna R. Rosinski, Kimberly S. Waggie, Jay F. Sarthy, Jacques Neefjes, Michael C. Haffner, Virginia J. Hoglund, Aaron Olson, Nicolas M. Garcia, Stephanie Walter, Darleen S. Tu, Harini Sadeeshkumar
article en

Abstract

Our study highlights Acla as a promising anthracycline derivative for pediatric cancers, with potent anti-tumor efficacy and a superior safety profile, even following prior anthracycline exposure. These results support continued investigation of chromatin-damaging anthracyclines that can kill pediatric cancer cells without inducing genotoxic stress. In addition, our studies underscore the need to refine preclinical models to better understand both acute and chronic anthracycline toxicities in pediatric and adolescent populations.

Pediatric Blood & CancerVol. 73(2)
Seattle Children's Hospital (US), University of Washington (US), Leiden University Medical Center (NL), Fred Hutch Cancer Center (US), Oncode Institute (NL)
CURE Childhood Cancer, University of Washington, Seattle Children's Research Institute, Sunbeam Foundation, Children’s Hospital of Wisconsin Research Institute, National Institutes of Health, National Cancer Institute
Openalex Percentile: Top 46%
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.